HaemophilusInfluenzae Type B Vaccine Market by Type and Application- Global Industry Analysis & Forecast to 2027
Published On : December 2020 Pages : 142 Category: Pharma & Healthcare Report Code : HC1213951
HaemophilusInfluenzae Type B VaccineMarket by Type(Liquid Combination HIB,Lyophilized Combination HIB,Liquid Monovalent HIB,Lyophilized Monovalent HIB)Application (Research Institutions,Hospital,Pharmaceutical and Biotechnology Companies,Academic Institutions)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
HaemophilusInfluenzae Type B VaccineMarket has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.The vaccination forhaemophilusinfluenzae type B beganin the 1970s when the first capsular polysaccharide vaccine that consisted of polyribosylribitol phosphate was created. Initially, the researchesassociated to these vaccines remained limited to United States of America and Canada.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Merck
- Novartis
- Lanzhou Institute of Biologica
- Sanofi
- Takeda Pharmaceuticals Company
- GlaxoSmithKline
- Walvax Biotechnology
- Immunize BC
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Haemophilus Influenzae Type B Vaccine Market, ByType, Estimates and Forecast, 2017-2027 ($Million)
o Liquid Combination HIB
o Lyophilized Combination HIB
o Liquid Monovalent HIB
o Lyophilized Monovalent HIB
· Haemophilus Influenzae Type B Vaccine Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Research Institutions
o Hospital
o Pharmaceutical and Biotechnology Companies
· Haemophilus Influenzae Type B Vaccine Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Merck
o Novartis
o Lanzhou Institute of Biologica
o Sanofi
o Takeda Pharmaceuticals Company
o GlaxoSmithKline
o Walvax Biotechnology
o Immunize BC
· Haemophilus Influenzae Type B Vaccine Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Haemophilus Influenzae Type B Vaccine Market, By Country
o U.S. Haemophilus Influenzae Type B Vaccine Market
o Canada Haemophilus Influenzae Type B Vaccine Market
o Mexico Haemophilus Influenzae Type B Vaccine Market
o Europe
§ Europe Haemophilus Influenzae Type B Vaccine Market, By Country
· Germany Haemophilus Influenzae Type B Vaccine Market
o UK Haemophilus Influenzae Type B Vaccine Market
o France Haemophilus Influenzae Type B Vaccine Market
o RussiaHaemophilus Influenzae Type B Vaccine Market
o Italy Haemophilus Influenzae Type B Vaccine Market
o Rest of Europe Haemophilus Influenzae Type B Vaccine Market
o Asia-Pacific
§ Asia-Pacific Haemophilus Influenzae Type B Vaccine Market, By Country
o ChinaHaemophilus Influenzae Type B Vaccine Market
o Japan Haemophilus Influenzae Type B Vaccine Market
o South KoreaHaemophilus Influenzae Type B Vaccine Market
o India Haemophilus Influenzae Type B Vaccine Market
o Southeast AsiaHaemophilus Influenzae Type B Vaccine Market
o Rest of Asia-Pacific Haemophilus Influenzae Type B Vaccine Market
o South America
§ South AmericaHaemophilus Influenzae Type B Vaccine Market
o Brazil Haemophilus Influenzae Type B Vaccine Market
o ArgentinaHaemophilus Influenzae Type B Vaccine Market
o ColumbiaHaemophilus Influenzae Type B Vaccine Market
o Rest of South America Haemophilus Influenzae Type B Vaccine Market
o Middle East and Africa
§ Middle East and AfricaHaemophilus Influenzae Type B Vaccine Market
o Saudi ArabiaHaemophilus Influenzae Type B Vaccine Market
o UAEHaemophilus Influenzae Type B Vaccine Market
o EgyptHaemophilus Influenzae Type B Vaccine Market
o NigeriaHaemophilus Influenzae Type B Vaccine Market
o South Africa Haemophilus Influenzae Type B Vaccine Market
o Rest of MEA Haemophilus Influenzae Type B Vaccine Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Haemophilus Influenzae Type B Vaccine Market, By Type
5.1. Introduction
5.2. Global Haemophilus Influenzae Type B Vaccine Revenue and Market Share by Type (2017-2021)
5.2.1. Global Haemophilus Influenzae Type B Vaccine Revenue and Revenue Share by Type (2017-2021)
5.3. Liquid Combination HIB
5.3.1. Global Liquid Combination HIB Revenue and Growth Rate (2017-2021)
5.4. Lyophilized Combination HIB
5.4.1. Global Lyophilized Combination HIB Revenue and Growth Rate (2017-2021)
5.5. Liquid Monovalent HIB
5.5.1. Global Liquid Monovalent HIB Revenue and Growth Rate (2017-2021)
5.6. Lyophilized Monovalent HIB
5.6.1. Global Lyophilized Monovalent HIB Revenue and Growth Rate (2017-2021)
6. Haemophilus Influenzae Type B Vaccine Market, By Application
6.1. Introduction
6.2. Global Haemophilus Influenzae Type B Vaccine Revenue and Market Share by Application (2017-2021)
6.2.1. Global Haemophilus Influenzae Type B Vaccine Revenue and Revenue Share by Application (2017-2021)
6.3. Research Institutions
6.3.1. Global Research Institutions Revenue and Growth Rate (2017-2021)
6.4. Hospital
6.4.1. Global Hospital Revenue and Growth Rate (2017-2021)
6.5. Pharmaceutical and Biotechnology Companies
6.5.1. Global Pharmaceutical and Biotechnology Companies Revenue and Growth Rate (2017-2021)
6.6. Academic Institutions
6.6.1. Global Academic Institutions Revenue and Growth Rate (2017-2021)
7. Haemophilus Influenzae Type B Vaccine Market, By Region
7.1. Introduction
7.2. Global Haemophilus Influenzae Type B Vaccine Revenue and Market Share by Regions
7.2.1. Global Haemophilus Influenzae Type B Vaccine Revenue by Regions (2017-2021)
7.3. North America Haemophilus Influenzae Type B Vaccine by Countries
7.3.1. North America Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2021)
7.3.2. North America Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Haemophilus Influenzae Type B Vaccine by Countries
7.4.1. Europe Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2021)
7.4.2. Europe Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Haemophilus Influenzae Type B Vaccine by Countries
7.5.1. Asia-Pacific Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Haemophilus Influenzae Type B Vaccine by Countries
7.6.1. South America Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2021)
7.6.2. South America Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Haemophilus Influenzae Type B Vaccine by Countries
7.7.1. Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Merck
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Novartis
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Lanzhou Institute of Biologica
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Sanofi
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Takeda Pharmaceuticals Company
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. GlaxoSmithKline
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Walvax Biotechnology
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Immunize BC
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
9. Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.1. Global Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Haemophilus Influenzae Type B Vaccine Market Forecast by Regions (2022-2027)
9.2.1. North America Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.1.1. United States Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.1.2. Canada Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.1.3. Mexico Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.2. Europe Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.2.1. Germany Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.2.2. France Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.2.3. UK Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.2.4. Russia Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.2.5. Italy Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.3. Asia-Pacific Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.3.1. China Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.3.2. Japan Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.3.3. Korea Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.3.4. India Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.4. South America Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.4.1. Brazil Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.4.2. Argentina Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.4.3. Columbia Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.4.4. Rest of South America Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.5. Middle East and Africa Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.5.3. Egypt Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.5.4. Nigeria Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.5.5. South Africa Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.5.6. Turkey Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Haemophilus Influenzae Type B Vaccine Market Forecast (2022-2027)
9.3. Haemophilus Influenzae Type B Vaccine Market Forecast by Type (2022-2027)
9.3.1. Haemophilus Influenzae Type B Vaccine Forecast by Type (2022-2027)
9.3.2. Haemophilus Influenzae Type B Vaccine Market Share Forecast by Type (2022-2027)
9.4. Haemophilus Influenzae Type B Vaccine Market Forecast by Application (2022-2027)
9.4.1. Haemophilus Influenzae Type B Vaccine Forecast by Application (2022-2027)
9.4.2. Haemophilus Influenzae Type B Vaccine Market Share Forecast by Application (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Haemophilus Influenzae Type B Vaccine Revenue and Revenue Share by Type (2017-2019)
Figure Global Liquid Combination HIB Revenue and Growth Rate (2017-2019)
Figure Global Lyophilized Combination HIB Revenue and Growth Rate (2017-2019)
Figure Global Liquid Monovalent HIB Revenue and Growth Rate (2017-2019)
Figure Global Lyophilized Monovalent HIB Revenue and Growth Rate (2017-2019)
Table Global Haemophilus Influenzae Type B Vaccine Revenue and Revenue Share by Application (2017-2019)
Figure Global Research Institutions Revenue and Growth Rate (2017-2019)
Figure Global Hospital Revenue and Growth Rate (2017-2019)
Figure Global Pharmaceutical and Biotechnology Companies Revenue and Growth Rate (2017-2019)
Figure Global Academic Institutions Revenue and Growth Rate (2017-2019)
Table Global Haemophilus Influenzae Type B Vaccine Revenue by Regions (2017-2019)
Figure North America Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure North America Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2019)
Figure North America Haemophilus Influenzae Type B Vaccine by Countries (2017-2019)
Figure North America Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure United States Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure United States Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Canada Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Mexico Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Europe Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2019)
Figure Europe Haemophilus Influenzae Type B Vaccine by Countries (2017-2019)
Figure Europe Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure Germany Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Germany Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure France Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure UK Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Russia Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Italy Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Rest of Europe Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Asia-Pacific Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Haemophilus Influenzae Type B Vaccine by Countries (2017-2019)
Figure Asia-Pacific Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure China Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure China Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Japan Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Korea Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure India Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Southeast Asia Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure South America Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2019)
Figure South America Haemophilus Influenzae Type B Vaccine by Countries (2017-2019)
Figure South America Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Brazil Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Argentina Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Columbia Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Rest of South America Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Haemophilus Influenzae Type B Vaccine by Countries (2017-2019)
Figure Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Saudi Arabia Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure United Arab Emirates Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Egypt Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Nigeria Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure South Africa Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Turkey Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Haemophilus Influenzae Type B Vaccine Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2017-2019)
Table Merck Haemophilus Influenzae Type B Vaccine Financial Overview
Table Novartis Haemophilus Influenzae Type B Vaccine Financial Overview
Table Lanzhou Institute of Biologica Haemophilus Influenzae Type B Vaccine Financial Overview
Table Sanofi Haemophilus Influenzae Type B Vaccine Financial Overview
Table Takeda Pharmaceuticals Company Haemophilus Influenzae Type B Vaccine Financial Overview
Table GlaxoSmithKline Haemophilus Influenzae Type B Vaccine Financial Overview
Table Walvax Biotechnology Haemophilus Influenzae Type B Vaccine Financial Overview
Table Immunize BC Haemophilus Influenzae Type B Vaccine Financial Overview
Figure Global Haemophilus Influenzae Type B Vaccine Revenue (Millions USD) and Growth Rate (2019-2027)
Table Haemophilus Influenzae Type B Vaccine Market Forecast by Regions (2019-2027)
Figure North America Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure United States Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Canada Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Mexico Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Europe Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Germany Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure France Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure UK Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Russia Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Italy Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Rest of Europe Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Asia-Pacific Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure China Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Japan Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Korea Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure India Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Southeast Asia Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure South America Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Brazil Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Argentina Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Columbia Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Rest of South America Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Middle East and Africa Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Saudi Arabia Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure United Arab Emirates Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Egypt Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Nigeria Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure South Africa Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Turkey Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Haemophilus Influenzae Type B Vaccine Market Forecast (2019-2027)
Figure Global Haemophilus Influenzae Type B Vaccine Forecast by Type (2019-2027)
Figure Global Haemophilus Influenzae Type B Vaccine Market Share Forecast by Type (2019-2027)
Figure Global Haemophilus Influenzae Type B Vaccine Forecast by Type (2019-2027)
Figure Global Haemophilus Influenzae Type B Vaccine Forecast by Application (2019-2027)
Figure Global Haemophilus Influenzae Type B Vaccine Market Share Forecast by Application (2019-2027)
Figure Global Haemophilus Influenzae Type B Vaccine Forecast by Application (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|